Researchers from Örebro University have found blood markers that may help identify individuals at risk of developing ulcerative colitis, a chronic inflammatory bowel disease. According to the research team, these markers can be present in the blood years before any symptoms appear.
The study involved analyzing blood samples from large population studies and focused on detecting a specific antibody known as anti-integrin αvβ6. The findings revealed that people who eventually develop ulcerative colitis often have these antibodies long before they are diagnosed.
Researchers suggest that this discovery could provide new insights into how ulcerative colitis develops at an early stage. In the future, it may lead to improved methods for identifying those at risk and allow for earlier intervention.
The results are being presented at the European Crohn's and Colitis Organisation (ECCO) Congress in Stockholm, which is dedicated to research on inflammatory bowel disease. The study was conducted through collaboration among several universities, including Örebro University, Uppsala University, Lund University, and Umeå University.
"ECCO is the largest congress in the field of IBD or inflammatory bowel disease, often attracting 8,000 or more attendees. Presenting our data at this congress offers great opportunities to forge new collaborations and gain valuable input on our research. Together, we can change and improve the future for our patients with IBD," said Jonas Halfvarson.
During the event, Jonas Halfvarson and his research team will receive an award for best researcher-initiated study for their work on NORDTREAT: a randomized, multicenter trial comparing different management strategies in newly diagnosed IBD patients.
